COMPASS PATHWAYS PLC (CMPS) Stock News
NASDAQ:CMPS - Nasdaq - US20451W1018 - ADR - Currency: USD
CMPS Latest News, Press Relases and Analysis
Agilysys, Amer Sports, X Financial And Other Big Stocks Moving Higher On Tuesday
COMPASS Pathways (CMPS) Upgraded to Buy: Here's What You Should Know
COMPASS Pathways (CMPS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Compass Pathways to Participate in 2025 RBC Capital Markets Global Healthcare Conference
Compass Pathways Announces First Quarter 2025 Financial Results and Business Highlights
Why Compass Pathways Stock Was a Double-Digit Winner This Week
Compass Pathways to Announce First Quarter Financial Results on May 8, 2025
Tesla Stock Climbs Despite Pulling Guidance, but Is More Downside Ahead?
Despite an abysmal quarter on nearly every metric, shares of Tesla (NASDAQ: TSLA) climbed even after the electric vehicle (EV) maker pulled its guidance for the year. The stock's rise can be attributed to CEO Elon Musk pledging to spend more time running the company instead of overseeing the Department of Government Efficiency (DOGE). Musk also continued to hype Tesla's robotaxi and artificial intelligence (AI) ambitions.
Bitcoin ETFs See $442M Daily Inflow As BTC Hovers Around $94,000
Spot Bitcoin ETFs registered $442 million in net inflows on April 24, marking five consecutive trading days of positive flows and pushing the cumulative inflow above $2.5 billion for the week. What Happened: Blackrock‘s (NASDAQ:IBIT) led the inflows ...
ASML Holding N.V. (ASML): Among AI Stocks That Will Skyrocket
We recently published a list of 10 AI Stocks That Will Skyrocket. In this article, we are going to take a look at where ASML Holding N.V. (NASDAQ:ASML) stands against other AI stocks that will skyrocket. AI (Artificial Intelligence) isn’t just a buzzword anymore—it’s becoming a part of our everyday lives, from the apps we […]
Jim Cramer Says He Prefers FedEx (FDX) Over UPS
We recently published a list of 10 Stocks on Jim Cramer’s Radar These Days. In this article, we are going to take a look at where FedEx Corporation (NYSE:FDX) stands against other stocks on Jim Cramer’s radar. Jim Cramer in a latest program on CNBC talked about the latest trends in the AI data center […]
Why Compass Pathways Stock Was a Double-Digit Winner This Week
Such a dynamic was in evidence with U.K.-based Compass Pathways (NASDAQ: CMPS) this week. On news about a step completed in a clinical trial, the company's shares rose by 13% over the period, according to data compiled by S&P Global Market Intelligence. Compass Pathways, which focuses on psilocybin -- the psychoactive compound found in "magic" mushrooms -- announced Tuesday that it had completed dosing in a late-stage clinical trial.
Compass Pathways Announces Completion of Recruitment for the Phase 3 COMP005 Trial of COMP360 Psilocybin for Treatment-Resistant Depression
Compass Pathways Announces Publication of Results from COMP004 Study on COMP360 Psilocybin for Treatment-Resistant Depression
Compass Pathways to Participate in Stifel Virtual CNS Forum
Mind Medicine's Net Losses Swell In Q4, But Retail Finds At Least 3 Reasons To Stay Bullish
The psychedelics treatment developer reported a net loss of $34.7 million for the quarter ended Dec. 31, 2024, widening from a $23.8 million loss a year earlier.
Mentions: MNMD
Compass Pathways Plc (CMPS) Q4 2024 Earnings Call Transcript
CMPS earnings call for the period ending December 31, 2024.
Compass Pathways Announces Fourth Quarter and Full-Year 2024 Financial Results and Business Highlights
Compass Pathways to Participate in TD Cowen 45th Annual Health Care Conference
Compass Pathways to announce fourth quarter and year-end financial results on February 27th, 2025
Mind Medicine Getting An 'RFK Bump'? Retail Gets More Bullish As Stock Heads For Best Day In Over 10 Months
Kennedy has previously advocated for decriminalizing psychedelics for therapeutic use, citing his son’s positive experience with the hallucinogenic brew ayahuasca.
RFK Jr. Confirmation Looms. How Kennedy Could 'Go Wild' On Health Care.
The Senate will vote Thursday on whether to put RFK Jr. in charge of health. It's unclear how he will impact biotech stocks.
Compass Pathways to Participate in Oppenheimer 35th Annual Healthcare Life Sciences Conference
Compass Pathways Appoints Steve Levine, M.D., as Chief Patient Officer
Compass Pathways Announces Pricing of Underwritten Offering
Compass Pathways to Be Added to the NASDAQ Biotechnology Index (NBI)
Compass Pathways to Participate in December Investor Conferences
Pfizer, Moderna, Novavax Take A Beating After Trump Taps Kennedy To Head Up HHS
President-elect Donald Trump tapped widely known vaccine skeptic Robert F. Kennedy Jr. to lead the Department of Health and Human Services.
Compass Pathways to participate in Stifel 2024 Healthcare Conference
LONDON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to...